



***BioAlliance Pharma accelerates its  
European clinical development of clonidine Lauriad™***

***The product becomes part of the Company's Orphan Oncology Business Unit***

**Paris, April 27, 2011** – BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced the extension of its ongoing clonidine Lauriad™ phase II clinical trial in chemoradiation therapy induced oral mucositis in patients with head and neck cancer to Germany and Spain. The expansion of the trial (currently ongoing in France) to two new countries will raise the total number of centers to over 40 and will help accelerate patient recruitment.

Based on the incidence of chemoradiation therapy induced oral mucositis in this population, BioAlliance Pharma plans to submit an application dossier to the European and US agencies in Q2 2011 to obtain an Orphan Drug designation for clonidine Lauriad™.

*“The orphan drug designation will qualify clonidine Lauriad™ for our “Orphan Oncology” Business Unit, which features breakthrough products for severe and rare cancers. In addition to clonidine Lauriad™, this Unit covers various projects including, at clinical stage, Livatag® (advanced hepatocellular carcinoma) in phase II and the AMEP® biotherapy (invasive metastatic melanoma) in phase I”,* comments Judith Greciet, Chief Operating Officer, Operations and R&D of BioAlliance Pharma.

BioAlliance Pharma second Business Unit “Specialty Pharma” includes both registered Loramyc® (oropharyngeal candidiasis in immunocompromised patients) and Setofilm® (chemo- and radiotherapy-induced nausea and vomiting), Sitavir® (recurrent herpes labialis), which is in registration phase, as well as other earlier projects which will contribute to generating revenues through partnering.

## **About BioAlliance Pharma**

Dedicated to Specialty Pharma and Orphan products in cancer treatment and in supportive care, with a focus on drug resistance, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

### **Specialty Pharma products**

Loramyc<sup>®</sup>/Oravig<sup>®</sup> (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US)  
Setofilm<sup>®</sup> (prevention and treatment of nausea and vomiting post chemo-radiotherapy and post operative) - Registered in EU  
Sitavir<sup>®</sup> (labialis herpes): Positive phase III final results; registration status  
Fentanyl Lauriad<sup>™</sup> (chronic cancer pain): Positive preliminary Phase I results

### **Orphan Oncology products**

Livatag<sup>®</sup> (Doxorubicin Transdrug<sup>™</sup>) in primary<sup>1</sup> liver cancer: Phase II results on survival  
Clonidine Lauriad<sup>™</sup> (chemoradiation therapy induced mucositis in H&N cancer): Phase II on going  
Biotherapy AMEP<sup>®</sup> (metastatic invasive melanoma): Phase I on going

*For more information, visit the BioAlliance Pharma web site at [www.bioalliancepharma.com](http://www.bioalliancepharma.com)*

### **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).*

### **BioAlliance Pharma SA**

Dominique Costantini, CEO  
Tel.: +33 1 45 58 76 01  
[dominique.costantini@bioalliancepharma.com](mailto:dominique.costantini@bioalliancepharma.com)  
Judith Greciet, COO  
Tel +33 1 45 58 70 61  
[judith.greciet@bioalliancepharma.com](mailto:judith.greciet@bioalliancepharma.com)  
Nicolas Fellmann, CFO  
Tel.: +33 1 45 58 71 00  
[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)

### **ALIZE RP**

Caroline Carmagnol  
Tel.: +33 6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)